Lower Proportion Of Patients Research Articles

1520. Mind the Clap: Reported Disseminated Gonococcal Infections in the United States, 2020–2022

Abstract Background Disseminated gonococcal infections (DGI) are estimated to occur in 0.5% to 3% of untreated Neisseria gonorrhoeae (GC) infections; however, surveillance and population-based studies to estimate DGI burden and describe recent DGI epidemiology and clinical manifestations are limited. In response to increased reports of DGI cases and clusters in the U.S., the Centers for Disease Control and Prevention (CDC) developed a surveillance system in 2020. We analyzed data captured by the initial two years of surveillance. Methods During 1/1/2020–3/31/2022, U.S. state/local health jurisdictions reported DGI cases to CDC utilizing a standardized case report form that collects demographic, sociobehavioral, and clinical information. A confirmed case was defined as isolation or detection of GC from a disseminated site of infection by culture or nucleic acid amplification test (NAAT); a probable case was defined as clinical manifestations of DGI and isolation or detection of GC from a mucosal site by culture or NAAT. Results In total, 274 DGI cases were reported to CDC from 13 U.S. states (65.7% from California): 215 (78.5%) confirmed cases and 59 (21.5%) probable cases. Among DGI cases, 51.1% were cisgender male, 33.2% were ≥ 45 years old, and 26.6% reported methamphetamine use in the past 12 months. Most patients (87.6%) did not have documented underlying immunosuppression or predisposing medical conditions. Among patients with DGI, 85.8% were hospitalized, 41.2% underwent related surgeries, and 2.2% died. Among confirmed cases, the most common disseminated sites of infection were synovial fluid (50.2%) and blood (45.1%). Among 184 (67.2%) patients with DGI who were tested for GC at a mucosal site, 115 (62.5%) were diagnosed with a mucosal GC infection (69.6% urogenital, 27.0% pharyngeal, 12.2% rectal); however, 85.5% of those not diagnosed with mucosal GC were only tested at urogenital sites. Only 89 patients (32.5%) reported mucosal symptoms present at the time of or within the month prior to DGI presentation. Conclusion Health care providers should maintain a high degree of suspicion for patients presenting with DGI symptoms given the potential for significant associated morbidity and the low proportion of patients who present with concurrent GC mucosal symptoms. Disclosures Alison Ridpath, MD, MPH, 3M company: Stocks/Bonds|Abbott Laboratories: Stocks/Bonds|Abbvie Inc.: Stocks/Bonds|Allogene Theraputics: Stocks/Bonds|Amarin Corperation PLC: Stocks/Bonds|infinity Pharmaceutical Companies: Stocks/Bonds|IQVIA Holdings Inc: Stocks/Bonds|Johnson and Johnson: Stocks/Bonds|Medtronic: Stocks/Bonds|pfizer: Stocks/Bonds|Thermo Fisher Scientific: Stocks/Bonds.

Introduction of a high dependency unit at a large paediatric and adolescent medicine department.

A goal has been set to establish paediatric high dependency units (PHDUs) in Norwegian hospitals. We sought to describe the patient population in one such unit, and to investigate whether the need for admission to an intensive care unit (ICU) changed after the unit was established. Information was obtained from electronic patient records, patient administration systems and the quality register for the PHDU at the Department of Paediatrics and Adolescent Medicine at Haukeland University Hospital. All patients admitted to the PHDU within five years of its opening in 2017 were included. A comparison was made between ICU patients in the five years before and the five years after the establishment of the PHDU. The PHDU had a total of 851 patient admissions in the period 2017-2021, increasing from 125 in 2017 to 247 in 2021. This accounted for 3.5% and 7.6% of the total number of patients admitted to the Department of Paediatrics and Adolescent Medicine in these years, respectively. The ICU had 185 paediatric patient admissions in the period 2012-2016 and 187 in the period 2017-2021, which constituted 0.9% and 1.1% of all patients admitted to the Department of Paediatrics and Adolescent Medicine during the periods, respectively. After the start-up of the PHDU, a lower proportion of patients were admitted to the ICU in the diagnostic groups diabetic ketoacidosis (15% in 2017-2021 versus 20% in 2012-2016) and sepsis (12% in 2017-2021 versus 19% in 2012-2016). The introduction of a PHDU was not associated with a simultaneous reduction in the number of ICU admissions overall. For diabetic ketoacidosis and sepsis, however, the proportion of transfers to the ICU was reduced.

Patient Reported Experience with Fatigue, a Cross Sectional Study Examining Indolent and Aggressive Lymphomas

Introduction Cancer-related fatigue (CRF) is a persistent, subjective sense of physical, emotional, or cognitive tiredness related to cancer or cancer treatment which negatively impacts functioning and quality of life (NCCN, 2015). The severity of CRF varies by lymphoma subtype, stage, and treatment received. Little information is known about patients’ experience with fatigue based on the rate of disease progression (indolent or aggressive lymphomas). This study aims to offer a unique insight into the fatigue experience of patients with indolent lymphomas compared to patients with aggressive lymphomas, using the Lymphoma Coalition (LC) 2022 Global Patient Survey (GPS) on Lymphomas and CLL. Methodology Globally, 8637 respondents comprised 7,113 patients and 1,524 caregivers from 84 countries completed the 2022 LC GPS. This analysis compared patients’ experience with fatigue in a subset of patients with aggressive lymphomas (n=2921) ('AL group') and indolent lymphomas (including CLL) (n=4573) ('IL group'). Demographics of both patient groups were used to analyze questions relating to patients’ experience of fatigue. Chi-square and p values were calculated as needed, and the statistical analyses were performed with IBM SPSS v27. Results Fatigue was the most reported symptom in both groups (IL group-67% and AL group -66%) (Table 1). While 46% of the AL group affected by fatigue as a symptom reported that their lymphoma treatment alleviated the fatigue, a lower proportion of patients in the IL group (37%) reported the same. Fatigue was also the top reported side effect for the IL group (65%) and the 2nd most reported side effect for the AL group (69%) (Table 1). When asked to rank the side effects that affected them the most, fatigue was one of the top 2 side effects, ranked 1 in both groups of patients (Table 1). Patients were asked to rate the severity of their fatigue on a scale of 1 to 10 (1 being minimal fatigue and 10 being the worst fatigue imaginable). Results indicated that a higher proportion of patients in the AL group (50%) rated the severity between 6 -10 compared to those in the IL group (42%). Conversely, a higher proportion of patients in the IL group had experienced fatigue for 2 years or more (57%) compared to the AL group (36%). These differences are statistically significant (Table 1). Regarding fatigue's effect on the quality of life, half or more patients in both groups reported that fatigue affected their ability to carry out their general and physical activities and daily housework. In addition, fatigue was shown to affect mood, social activities, and enjoyment of life (Table 1). Two-thirds of the IL group reported they had discussed their fatigue with their doctors in the last two years (from survey time), compared to half of the AL group. Over half of the patients in both groups reported that their doctors did not follow up on their fatigue (Table 1). Patients reported 'information about normal vs cancer-related fatigue and 'strategies to manage their fatigue as the top information given by their doctors, while 41% of the IL group were not provided with any information on fatigue by their doctors compared to 28% of AL group (Figure 1). Balancing time schedules was the top reported coping strategy in both groups (IL group-46% vs AL group- 42%). Exercise programs and mind-body interventions followed. Conclusion The results show that fatigue is the leading physical issue affecting the well-being of patients with indolent and aggressive lymphomas. However, some differences exist in how patients may experience fatigue in terms of fatigue severity and duration. These differences may be because aggressive and indolent lymphomas often differ in symptom presentation, severity, treatment type or whether patients communicate their fatigue with their doctor. Over 50% of all patients reported that when they expressed their fatigue to their doctor, they felt it was not addressed or followed up. Given the multifactorial nature of fatigue, there is no standard treatment, and interventions that may help improve fatigue must be explored to treat underlying causes. The data highlights that regardless of lymphoma type, fatigue needs to be recognized and treated at all stages of a patient's disease, according to standard clinical practice guidelines. Healthcare providers and patients need to improve their communication about fatigue. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Glasgow-Blatchford score combined with nasogastric aspirate as a new diagnostic algorithm for patients with nonvariceal upper gastrointestinal bleeding.

The Glasgow-Blatchford score (GBS) is a widely used risk assessment tool for patients with upper gastrointestinal bleeding. However, it only identifies a relatively low proportion of patients at low risk for adverse events and poor outcomes. We developed a simple diagnostic algorithm combining the GBS and nasogastric aspirate and evaluated its diagnostic performance. A total of 115 consecutive patients with suspected nonvariceal upper gastrointestinal bleeding who underwent nasogastric tube placement and upper endoscopy at our emergency department were prospectively evaluated. We compared the diagnostic accuracy of the GBS and our algorithm for predicting high-risk endoscopic lesions (HRELs) using receiver operating characteristic curve analysis. Thirty-five patients had HRELs. Compared with the GBS, our algorithm showed superior performance with respect to the prediction of HRELs (area under the curve, 0.639 and 0.854, respectively; p<0.001). With set optimal threshold values, the algorithm identified a significantly higher proportion of patients who did not have HRELs than the GBS (23.5%vs. 2.6%, p<0.001). The novel algorithm has improved the diagnostic performance of the GBS and predicted more patients who did not have HRELs than the GBS alone. After further validation, it may be a useful tool for making clinical management decisions for patients with nonvariceal upper gastrointestinal bleeding.

Prolonged length of stay is associated with reduced hand hygiene compliance in the emergency department: A single centre retrospective study.

To examine whether patient flow factors in the ED such as prolonged length of stay are associated with hand hygiene (HH) compliance. We conducted a retrospective study at an urban district hospital utilising available data from January 2018 to December 2021. Compliance to the World Health Organization five moments of HH expressed as percentage of total moments observed were collated every 2 months. Patient flow measures including proportion of patients referred or discharged within 4h (LOS4), proportion of patients with ED length of stay >24 h (LOS24) and total number of patient presentations, were obtained for each 2-month periods. The association between these patient flow measures and HH compliance was examined using Pearson's correlation (P < 0.05). The results showed a moderate and significant association between rates of HH compliance and LOS24 (r=-0.48, P=0.025). That is, lower proportion of patients with ED length of stay >24 h was associated with improved HH compliance. There was no significant correlation between HH compliance and LOS4 (r=0.38, P=0.085) or total number of ED presentations (r= -0.30, P=0.17). The findings show that prolonged ED length of stay may explain, at least partly, lower rates of HH compliance. Improvements in ED HH compliance should also include strategies that enhance patient flow.

Nonadherence to appropriate tidal volume and PEEP in children with pARDS at a single center.

Low tidal volume and adequate positive end-expiratory pressure (PEEP) are evidence-based approaches for pediatric acute respiratory distress syndrome (pARDS), however, data are limited regarding their use since pARDS guidelines were revised in 2015. To identify prevalence of, and factors associated with, nonadherence to appropriate tidal volume and PEEP in children with pARDS. Retrospective cohort study of children 1 month to <18 years with pARDS who received invasive mechanical ventilation from 2016 to 2018 in a single pediatric intensive care unit (PICU). At 24 h after meeting pARDS criteria, 48/86 (56%) patients received tidal volume ≤8 ml/kg of ideal body weight and 45/86 (52%) received appropriate PEEP, with 22/86 (26%) receiving both. Among patients ≥2 years of age, a lower proportion of patients with overweight/obesity (9/25, 36%) had appropriate tidal volume versus those in the normal or underweight category (16/22, 73%, p = 0.02). When FIO2 was ≥50%, PEEP was appropriate in 19/60 (32%) cases versus 26/26 (100%) with FIO2 < 50% (p < 0.0001). pARDSwas documented in the progress note in 7/86 (8%) patients at 24 h. Severity of pARDS, documentation in the progress note, and other clinical factors were not significantly associated with use of appropriate tidal volume and PEEP, however pARDS was documented more commonly in patients with severe pARDS. In a single PICU in the United States, children with pARDS did not receive appropriate tidal volume for ideal body weight nor PEEP. Targets for improving tidal volume and PEEP adherence may include overweight patients and those receiving FIO2 ≥ 50%, respectively.

Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism.

Simple SummaryThe combination of CDK4/6 inhibitors and endocrine therapy is now considered the standard of care for patients with estrogen receptor-positive (ER+) breast cancer. The emerging tide of CDK4/6 inhibitor resistance urges more research to explore underlying resistance mechanisms. This study profiled circulating cell-free DNA obtained before and after palbociclib treatment in ER+ metastatic breast cancer patients using 91-gene panel sequencing. The results revealed that the acquisition of CCNE1 mutations and the loss of TSC2 mutations confer an unfavorable prognosis, suggesting that these mutations may potentially serve as novel genomic biomarkers for treatment resistance. Future large-scale population studies and mechanism-focused research are needed to confirm the findings of this study and elucidate the underlying molecular mechanisms. Ultimately, such efforts may lead to the development of improved methods to predict treatment efficacy and clinical outcomes, as well as more effective targeted treatment approaches for the benefit of breast cancer patients.Previously undescribed molecular mechanisms of resistance will emerge with the increased use of cyclin-dependent kinase 4/6 inhibitors in clinical settings. To identify genomic aberrations in circulating tumor DNA associated with treatment resistance in palbociclib-treated metastatic breast cancer (MBC) patients, we collected 35 pre- and post-treatment blood samples from 16 patients with estrogen receptor-positive (ER+) MBC, including 9 with inflammatory breast cancer (IBC). Circulating cell-free DNAs (cfDNAs) were isolated for sequencing using a targeted panel of 91 genes. Our data showed that FBXW7 and CDK6 were more frequently altered in IBC than in non-IBC, whereas conversely, PIK3CA was more frequently altered in non-IBC than in IBC. The cfDNA samples collected at follow-up harbored more mutations than baseline samples. By analyzing paired samples, we observed a higher percentage of patients with mutations in RB1, CCNE1, FBXW7, EZH2, and ARID1A, but a lower proportion of patients with mutated TSC2 at the post-treatment stage when they developed progression. Moreover, acquisition of CCNE1 mutations or loss of TSC2 mutations after treatment initiation conferred an unfavorable prognosis. These data provide insights into the relevance of novel genomic alterations in cfDNA to palbociclib resistance in MBC patients. Future large-scale prospective studies are warranted to confirm our findings.

Improving access to cancer genetic testing for underserved women in southeast Texas.

6548 Background: Hereditary breast cancer accounts for 5-10% of all cases, but only 20% of eligible women undergo NCCN guideline-concordant screening. We demonstrated previously that our simple genetic risk screening tool (GRST) and telegenetics improved adherence to genetic testing guidelines and increased high-risk cancer surveillance. Our objective was to identify women eligible for genetic testing using breast cancer screening clinics in underserved communities as entry points, reach them with our tailored program, and measure impact. Methods: This is a prospective study in women presenting for breast cancer screening at The Rose, which provides breast imaging to underserved patients in Houston, TX. Women who consented to participate filled out the GRST and provided socio-demographic information. Those at high risk for hereditary cancer after GRST scoring were provided with educational materials and sent a saliva-based genetic testing kit. When results included a pathogenic variant (PV) or variant of uncertain significance (VUS), individuals received telegenetic counseling and risk reduction resources. Others were notified of negative results by phone. The program included education for providers about importance of genetic testing. Socio-demographic characteristics were analyzed using descriptive statistics. All statistical tests were two-sided. Results: 501 women filled out the GRST. Median age was 52. Median annual salary was $45,000 (IQR 21-75K). 151 (36.3%) were uninsured. 252 (50.3%) identified as White, 230 (45.9%) as Hispanic/Latino, and 106 (21.2%) as Black/African American. 150 (33%) were eligible for genetic testing; 100 could be contacted. Of the 100, 41 declined testing, 40 were lost to follow-up, 19 agreed, and 15 (10% of those eligible) returned the kits. Results included 11 negative, 2 VUS, 1 PV (NF1). Among 41 who declined testing, reported reasons included not wanting to know the results or preference to follow-up with their primary care doctor in 11 (26.8%) each, not enough time or prior genetic testing in 6 (14.6%) each, no reason given by five, and perception that testing was unnecessary in two. Completion of genetic testing was not associated with insurance, salary, family history, or race/ethnicity (p &gt; 0. 05). Conclusions: Our study was successful in identifying underserved women at high risk of hereditary cancer who have not previously undergone genetic testing using a simple screening tool. We reduced barriers to genetic testing by working with a trusted community organization and using remote testing and telegenetics. We did not find any factors associated with genetic testing completion, though results are limited by small sample size. Given the low proportion of patients who completed testing, the next project phase will focus on improving convenience for patients and exploring patient and program-related reasons for non-completion of testing and strategies to overcome these.

The adverse effect of the COVID-19 pandemic on health service usage among patients with type 2 diabetes in North Karelia, Finland

AimsThe COVID-19 pandemic has challenged health systems and their capacity to deliver essential health services while responding to COVID-19. This study examines the pandemic’s impact on health service usage among patients with type 2 diabetes in the North Karelia region, in Finland.MethodsThis retrospective cohort study used electronic health records of 11,458 type 2 diabetes patients, comprising all primary and specialised care contacts in 2019 and 2020. We analysed diabetes and dental healthcare contacts to primary care nurses, doctors and dentists and all emergency visits in specialised care. We compared healthcare usage in three different periods in 2020 (pre-lockdown [1 January–15 March], lockdown [16 March–31 May], post-lockdown [1 June–31 December]) with the equivalent period in 2019.ResultsDuring the lockdown period, the number of diabetes-related contacts decreased significantly but quickly increased again to nearly the same level as in 2019. Overall, healthcare usage was lower in the pandemic year, with proportionally 9% fewer contacts per person (mean 2.08 vs 2.29) and a proportionally 9% lower proportion of patients making any contact (59.9% vs 65.8%). The proportion of remote consultations was similar in both years in the pre-lockdown period (56.3–59.5%) but then increased to 88.0% during the 2020 lockdown. Patterns were similar when analysed by age group and gender. Emergency visits went down significantly at the beginning of the lockdown period, but a “rebound effect” was observed, so after the lockdown, the number of emergency visits in 2020 exceeded the numbers of the previous year.ConclusionDespite the COVID-19 pandemic, diabetes care was continuous, and even elderly patients aged ≥70 years accessed the health services. The delivery of many essential services was facilitated by processes that strongly relied on telemedicine already before the pandemic.

Relationship between Dietary Behaviors and Physical Activity and the Components of Metabolic Syndrome: A Case-Control Study.

Poor diet and low physical activity play an important role in the etiopathogenesis of metabolic syndrome. The aim of this study was to analyze the association between nutrient intake, groups of food products and physical exercise undertaken and the components of metabolic syndrome (MS). The study included 330 patients with MS, and the control group comprised of 270 subjects without MS. The food intake was assessed using 24-h dietary recall, and a 13-item Food Frequency Questionnaire. To assess nutrition knowledge, a Beliefs and Eating Habits Questionnaire was used. The level of physical activity was assessed using the International Physical Activity Questionnaire. Three patterns of behavior were identified: Prudent-Active, Western-Sedentary, and NotPrudent-notWestern-lowActive. In the Prudent-Active group, as compared to the NotPrudent-notWestern-lowActive subjects, the risk of central obesity, hypertension, hypertriglyceridemia, low HDL cholesterol and hyperglycemia occurrence was lower. There was also a lower proportion of patients with MS. As compared to the NotPrudent-notWestern-lowActive subjects, in the Prudent-Active group there was more than a two times higher chance of subjects with a high level of nutrition knowledge. Western diets have been proven to exert a detrimental effect on the components of MS. When designing intervention programs, education of patients with MS on dietary habits and physical activity should be considered.

Clinical characteristics and survival of children with hypertrophic cardiomyopathy in China: A multicentre retrospective cohort study.

SummaryBackgroundFew data on paediatric hypertrophic cardiomyopathy (HCM) are available in developing countries. A multicentre, retrospective, cohort study was conducted to profile the clinical characteristics and survival of children with HCM in China.MethodsWe collected longitudinal data on children with HCM aged 0–18 years at three participating institutions between January 1, 2010 and December 31, 2019. Patients were identified by searching for the diagnosis using ICD-10 codes from the electronic medical records database. HCM was diagnosed morphologically with echocardiography or cardiovascular magnetic resonance imaging. The exclusion criteria were secondary aetiologies of myocardial hypertrophy. The primary outcomes were all-cause death or heart transplantation. The Kaplan–Meier method was used to estimate the survival rate of different groups.FindingsA total of 564 children were recruited, with a median age at diagnosis of 1.0 year (interquartile range, IQR: 0.4–8.0 years), followed for a median of 2.6 years (1977 patient-years, IQR:0.5, 5.9 years). The underlying aetiology was sarcomeric (382, 67.7%), inborn errors of metabolism (IEMs) (108, 19.2%), and RASopathies (74, 13.1%). A total of 149 patients (26.4%) died and no patients underwent heart transplantation during follow-up. The survival probability was 71.1% (95% confidence interval [CI], 66.3%–75.3%) at 5 years. Patients with IEMs or those diagnosed during infancy had the poorest outcomes, with an estimated 5-year survival rate of 16.9% (95% CI, 7.7%–29.1%) and 56.0% (95% CI, 48.8%–62.5%), respectively. Heart failure was the leading cause of death in the cohort (90/149, 60.4%), while sudden cardiac death was the leading cause in patients with sarcomeric HCM (32/66, 48.5%).InterpretationThere is a high proportion of patients with IEM and a low proportion of patients with neuromuscular disease in children with HCM in China. Overall, mortality remains high in China, especially in patients with IEMs and those diagnosed during infancy.FundingNational Natural Science Fund of China (81770380, 81974029), China Project of Shanghai Municipal Science and Technology Commission (20MC1920400, 21Y31900301).

Needle-Warming Moxibustion plus Multirehabilitation Training to Improve Quality of Life and Functional Mobility of Patients with Rheumatoid Arthritis after Medication

Objective Patients treated with medication for rheumatoid arthritis (RA) often improve but continue to have active diseases. The study aims to investigate whether needle-warming moxibustion (NWM) plus multirehabilitation training can improve quality of life (QoL) and functional mobility of RA patients after medication. Methods Eighty-four RA patients were selected as study participants, including 42 patients receiving medication (medication group) and 42 patients receiving NWM plus multirehabilitation training (NWM + MRT group). The scores of disease symptoms, pain (visual analogue scale (VAS)), sleep quality (Pittsburgh Sleep Quality Index (PSQI)), functional mobility (Fugl–Meyer assessment scale (FMAS)), self-rating anxiety scale (SAS), self-rating depression scale (SDS), and QoL (SF-36) were compared before and after treatment. When patients were discharged from the hospital, they were given a questionnaire for treatment satisfaction. Results After treatment, decreases in the scores of the VAS, PSQI, SAS, and SDS were observed in both cohorts, especially in the NWM + MRT group (P < 0.05). The FMAS scores of upper limbs and lower limbs were increased after treatment, which were higher in the NWM + MRT group in comparison with the medication group (P < 0.05). Of note, patients in the NWM + MRT group scored higher in various dimensions of the SF-36 scale (P < 0.05), showing better QoL. The satisfaction survey showed that the NWM + MRT group had a higher proportion of patients being satisfied and a lower proportion of patients being dissatisfied (P < 0.05). Conclusion NWM plus multirehabilitation training could significantly attenuate disease symptoms, improve QoL, recover functional mobility, and reduce the risk of anxiety and depression in RA patients.

MO226: Is Remission of Hematuria Associated with Kidney Outcome in Biopsy-Proven Primary IGA Nephropathy?

Abstract BACKGROUND AND AIMS Microscopic hematuria, associated with variable proteinuria, is the most common clinical feature of IgA nephropathy (IgAN). However, its role in the disease progression is still controversial. This study aims to assess whether remission of hematuria is associated with kidney outcome in adults with primary IgAN. METHOD This retrospective, longitudinal study enrolled 62 adults, out of 214 with biopsy-proven IgAN between 1 January 2008 and 31 December 2017 {age 41 [95% confidence interval (CI) 37–46] years, 73% males, eGFR 41.3 (95% CI 33.1–51) mL/min and proteinuria 1.1 (95% CI 0.9–1.6) g/g} who had at least three assessment visits 3 months apart until 31 May 2018. The median follow-up period was 68 (95% CI 58.6–77.3) months. Demographic (age, gender), comorbidities, clinical and laboratory data (proteinuria, hematuria and blood pressure) at the time of kidney biopsy and during the follow-up period were retrieved from medical records. Information about therapy was also recorded. The study endpoint was kidney death defined as doubling of serum creatinine or renal replacement therapy (RRT) initiation. Kidney survival was evaluated by Kaplan–Meier method and variables related to kidney outcome by multivariate Cox proportional hazard modeling. Remission of hematuria was defined as ≤ 5 red blood cells/high power field in at least two samples taken no less than 3 months apart. Subjects were grouped as remission of hematuria (n = 24) and persistent hematuria (n = 38). RESULTS There were no differences between the two groups regarding demographic characteristics, comorbidities, kidney function, proteinuria, hematuria or inflammation markers at time of kidney biopsy. During the follow-up period, remission of proteinuria (defined as a &amp;gt; 50% decrease in urinary protein-to-creatinine ratio from baseline) was found in more than half of the group with remission of hematuria but in less than a quarter of group with persistent hematuria (57.1% versus 24.2%; P = .02). However, systolic blood pressure was well controlled (&amp;lt;130 mmHg) in similar proportions (63.6 versus 57.9%, P = .7) and a comparable reduction in mean arterial blood pressure from the baseline was observed [ΔMAP −7.8 (95% confidence interval (CI) −14.1 to −0.45) versus −2.8 (95% CI −9.7–4.9) mmHg; P = .2] in both groups. A high proportion of patients were treated with renin–angiotensin inhibitors (71 versus 61%; P = .5) and almost a third received immunosuppressive therapy (38 versus 34%; P = .8), similarly in the two groups. During the follow-up, a lower proportion of patients with remission of hematuria reached the composite kidney endpoint (16.7 versus 42.1%, P = .03). In the univariate time-dependent analysis, the kidney survival was numerically better in patients with remission of hematuria [(71.4 (95% CI 64.5–78.2) versus 66.02 (95% CI 54.7–77.2) months; log rank P = .06; Fig. 1A]. However, in the multivariate time-dependent analysis, only the absence of proteinuria remission [OR 0.06 (95%CI 0.008–0.46), P = .007] and a lower baseline eGFR [OR 0.96 (95% CI 0.93–0.98), P = .007] were associated with a poor kidney outcome (chi-squared = 18.5, P &amp;lt; .001) (Fig. 1B). CONCLUSION In this cohort of young adults with biopsy-proven primary IgA nephropathy and moderate decline in kidney function, the remission of hematuria for at least 3 months was not associated with kidney outcome.

MO532: Cardiovascular Events in Patients With Non–Dialysis-Dependent Chronic Kidney Disease and Anemia: Regional Analysis of Patients Previously Treated With Erythropoiesis-Stimulating Agents in the PRO2TECT Trial

Abstract BACKGROUND AND AIMS Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor being investigated for the treatment of anemia due to chronic kidney disease (CKD). In global phase 3 trials, vadadustat has demonstrated non-inferiority to darbepoetin alfa for time to major adverse cardiovascular event (MACE) in patients with dialysis-dependent CKD (INNO2VATE trials), but not with non–dialysis-dependent CKD (NDD-CKD; PRO2TECT trials) [1, 2]. In a prespecified subgroup analysis of the PRO2TECT trials, a difference in the relative safety between vadadustat and darbepoetin alfa was observed between the US and non-US regions [1]. We investigated regional differences in MACE in patients with NDD-CKD-administered vadadustat and darbepoetin alfa who were previously treated with erythropoietin-stimulating agents (ESAs) in the PRO2TECT trials. METHOD Two phase 3, open-label, randomized, active-controlled clinical trials comparing vadadustat with darbepoetin alfa were conducted in North America, Latin America, Europe, Africa, and the Asia-Pacific region. This post hoc analysis evaluated MACE in patients in the PRO2TECT trial who were actively maintained on ESAs at study entry with ≥1 dose received within 6 weeks before or during screening (Conversion trial; NCT02680574) and who received ≥1 dose of trial drug, stratified by region (USA versus Europe versus non-US/non-Europe). MACE was defined as a composite of death from any cause, nonfatal myocardial infarction or nonfatal stroke. Expanded MACE was defined as MACE plus hospitalization for heart failure or thromboembolic event, excluding vascular access failure. RESULTS A total of 1723 ESA-treated patients were randomized in the conversion trial of the PRO2TECT program and received ≥1 dose of study drug, including 665 patients in the USA, 444 in Europe, and 614 outside the USA and Europe. Europe had a lower proportion of patients with diabetes and more patients who had received intravenous (IV) iron, while patients in the non-US/non-European region were younger and had a lower prevalence of cardiovascular (CV) disease. A higher proportion of patients in Europe were using darbepoetin alfa at baseline than in other regions (59%–63% versus 14%–28%), though ESA dose was lower (57–61 versus 93–149 IV epoetin equivalent U/kg/week). The hazard ratio for MACE in the overall population for vadadustat versus darbepoetin alfa was 1.16 (95% CI 0.93–1.45). Across regions, event rates were similar in the vadadustat groups, but event rates in the darbepoetin alfa group were lower in Europe compared with the US and non-US/non-Europe (Table 1), which was driven by fewer total deaths (non-CV and CV) reported in Europe in the darbepoetin alfa arm (n = 24/220) compared with the vadadustat arm (n = 38/224) (Table 2). Additional post hoc analyses of MACE accounting for several baseline characteristics, including ESA dose, did not alter the outcomes of the study. CONCLUSION Regional differences in time to first MACE were observed in patients with NDD-CKD who were treated with ESA and randomized to receive vadadustat or darbepoetin alfa as part of the PRO2TECT program. It remains unclear if the lower risk of MACE observed in Europe with the darbepoetin alfa group was related to differences in unobserved baseline characteristics, regional treatment practices, methodological reasons or chance.

Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD \u2018real world\u2019 study

IntroductionChronic obstructive pulmonary disease (COPD) guidelines recommend reserving triple therapy of inhaled corticosteroid (ICS), long-acting β2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) for patients with exacerbations despite dual therapy. However, many patients receive triple therapy without a clear indication. For these patients, it would be useful to know whether ICS can be withdrawn.MethodsDACCORD was a longitudinal, non-interventional ‘real-world’ study in three cohorts. This manuscript describes the results of Cohort 3, which recruited patients with COPD who had received triple therapy for ≥ 6 months. Prior to entry, each patient’s physician decided to continue triple therapy, or switch to a LABA/LAMA; patients were then followed for 12 months, with exacerbations and COPD Assessment Test (CAT) data recorded every 3 months. The primary endpoint was the time until COPD worsening, defined as the occurrence of a moderate/severe exacerbation or clinically relevant CAT worsening.ResultsOf the 1192 patients recruited into the study, 967 completed the end-of-study visit and ≥ 2 of the three interim visits, 292 and 675 receiving LABA/LAMA and triple therapy, respectively. Most baseline demographics were similar between the two groups. A lower proportion of patients in the LABA/LAMA group had COPD worsening than with triple therapy (32.5% vs 55.7% at 12 months), with the time to worsening extended in the LABA/LAMA group (hazard ratio 2.004, p < 0.001). In addition, a significantly lower proportion of patients in the LABA/LAMA group exacerbated (18.5% vs 28.7%; p < 0.001), accompanied by a greater improvement from baseline in CAT total score. Overall, fewer patients in the LABA/LAMA group reported adverse events than in the triple therapy group (12.9% vs 15.1%).ConclusionsThese results suggest that in a real world setting physicians are able to identify patients who can be ‘stepped down’ from triple therapy to LABA/LAMA. Following step down, there was no overall decline in COPD—indeed, some patients had better outcomes.

MP25-11 PREDICTORS OF SURGICAL SUCCESS FOR ROBOTIC URETERAL RECONSTRUCTION OF PROXIMAL AND MIDDLE URETERAL STRICTURES

You have accessJournal of UrologyCME1 May 2022MP25-11 PREDICTORS OF SURGICAL SUCCESS FOR ROBOTIC URETERAL RECONSTRUCTION OF PROXIMAL AND MIDDLE URETERAL STRICTURES Matthew Lee, Ziho Lee, Randall Lee, David Strauss, Rohit Reddy, Lee C. Zhao, Michael D. Stifelman, and Daniel Eun Matthew LeeMatthew Lee More articles by this author , Ziho LeeZiho Lee More articles by this author , Randall LeeRandall Lee More articles by this author , David StraussDavid Strauss More articles by this author , Rohit ReddyRohit Reddy More articles by this author , Lee C. ZhaoLee C. Zhao More articles by this author , Michael D. StifelmanMichael D. Stifelman More articles by this author , and Daniel EunDaniel Eun More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002568.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We investigate predictors of surgical success for patients undergoing robotic ureteral reconstruction (RUR) for proximal and middle ureteral stricture disease. METHODS: We retrospectively reviewed our multi-institutional Collaborative of Reconstructive Robotic Ureteral Surgery (CORRUS) database to identify all consecutive patients undergoing RUR for proximal and/or middle ureteral stricture disease between 04/2012-01/2019. The specific reconstruction technique was determined by the primary surgeon based on clinical history and intraoperative findings. Patients were grouped according to whether or not they were surgical successful. Preoperative variables between both groups were compared using chi-square tests. All independent variables with associations of p<0.2 then underwent a binary logistic regression analysis to determine predictive variables of success for RUR (p≤0.05 was considered statistically significant). RESULTS: Overall, 228 patients met inclusion criteria. Univariate analysis (Table 1) showed that there were a lower proportion of patients with diabetes (8.5% versus 29.6%, p<0.01) and a higher proportion of patients who underwent ureteral rest (84.5% versus 63.0%, p=0.01) in the surgical success group. Multivariate logistic regression analysis (Table 2) further revealed that patients with diabetes were 3.74 times more at risk (p=0.01, CI: 1.35-10.37) of failing to achieve surgical success compared to those without diabetes. Patients undergoing ureteral rest prior to RUR were 2.68 times more likely (p=0.04, CI: 1.05-6.82) to achieve surgical success compared to those who did not undergo ureteral rest. CONCLUSIONS: In patients undergoing RUR for management of proximal and middle ureteral strictures, preoperative factors such as the absence of diabetes and the implementation of ureteral rest may optimize surgical outcomes. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e432 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Matthew Lee More articles by this author Ziho Lee More articles by this author Randall Lee More articles by this author David Strauss More articles by this author Rohit Reddy More articles by this author Lee C. Zhao More articles by this author Michael D. Stifelman More articles by this author Daniel Eun More articles by this author Expand All Advertisement PDF DownloadLoading ...

The Effect of A Home Exercise Program on Visio-Vestibular Function in Concussed Pediatric Patients

Background:A home exercise program (HEP) can provide an equitable and cost-effective method for therapy targeted towards visio-vestibular deficits that are common following concussion. It is unclear if pediatric patients prescribed a HEP demonstrate improved visio-vestibular function.Purpose:To explore if a HEP affects visio-vestibular function in concussed pediatric patients.Methods:This observational study included 1,041 patients (614 female(59.0%); age=14.0±2.5 years) reporting to a specialty care concussion center for an initial visit within 28 days of injury and a first follow-up visit within 60 days of injury. All patients completed a Visio-Vestibular Examination (VVE) at both time points, which consisted of 9 maneuvers: smooth pursuit, horizontal/vertical saccades and gaze stability, binocular convergence, left/right monocular accommodation, and complex tandem gait. Patients were given a HEP at initial visit which consisted of exercises, including saccades, gaze stability, convergence, and balance, and instructed to complete these exercises 1-2 times daily. At follow-up, patients were asked to report their progress with the HEP, which was categorized as 1) has not done the HEP, 2) is currently doing the HEP, or 3) has completed the HEP. Primary outcomes included HEP status at first follow-up, VVE subtests (normal/abnormal), and total VVE (abnormal=2+ abnormal subtests). Separate chi-square tests with Bonferroni corrections were used to determine if the proportion of abnormal VVE outcomes was associated with HEP status (α=0.017 a priori).Results:At initial visit, 812 (77.6%) patients presented with abnormal total VVE. The proportion of abnormal subtests at initial visit ranged from 16.0% (right monocular accommodation) to 77.4% (horizontal gaze stability). At first follow-up, the proportion of abnormal total VVE did not differ among patients reporting not doing the HEP (101(62.0%)), patients currently doing the HEP (516(69.0%)), and patients who had completed the HEP (51(69.0%)). However among VVE subtests, a lower proportion of patients who completed the HEP presented with abnormal smooth pursuit (7.5%), horizontal (3.8%) and vertical (3.8%) saccades, and complex tandem gait (0%) relative to patients who were currently doing the HEP (P≤0.003) and to patients not doing the HEP (P≤0.01).Conclusions:Our findings indicate that patients who completed the HEP presented with better aspects of visio-vestibular function (smooth pursuit, saccades, and complex tandem gait) relative to those who did not start or were currently doing the HEP. This suggests that a HEP may be effective in reducing visio-vestibular dysfunction following concussion. Additional research investigating cost-effective concussion management tools is needed to improve patient outcomes.

The Influence of Living in Rural Areas on the Evolution and Management of Pediatric Ovarian Cystic Lesions: A Retrospective Study on a Cohort from South Eastern Romania

BackgroundThe incidence of ovarian cystic lesions (OCLs) in pediatric patients has been increasing in recent years. An early diagnosis is mandatory for a favourable prognosis but it depends on the primary medical care services and on the socioeconomic status of the patient. The present study aims at assessing the prevalence and the age-specific frequencies of pediatric OCLs, as well as identifying disparities between subjects in the urban and the rural areas, in order to explore the extent to which OCLs occurrence, diagnosis, evolution and treatment differ in the case of patients living in rural areas.MethodsA 3-year retrospective study was conducted between 2017 and 2019. All the female patients aged between 0 and 18 with OCLs ≥10 mm (N = 488), diagnosed and treated at “Sf.Ioan” Clinical Emergency Hospital for Children in Galaţi were included in the study. The Chi2 test was used for comparing the distributions of frequencies, and the t-Student test was used for comparing the means of any two normally distributed variables. The statistical significance threshold (p) was set at 0.05.ResultsThe prevalence of OCLs ≥10 mm was 14.85%, 47.13% of the subjects originating in rural area (p = 0.62). Different from the urban areas, the rural ones are characterised by a lower proportion of patients with BMI ≥25 (p = 0.002), larger OCLs mean size (p = 0.278), a more frequent complex aspect on ultrasonography (p = 0.01), and a smaller number of general physician referrals (p = 0.005). Moreover, a higher proportion of rural patients were intraoperatively diagnosed with OCLs (p = 0.044), had complicated OCLs (p = 0.012) and had their OCLs surgically treated OCLs (p < 0.01).ConclusionTaking into consideration the socio-economic situation of south eastern Romania, patients living in rural areas have proven exposed to a higher risk of presenting with larger, complex and complicated OCLs, which most often require surgical treatment.

Exploring the Changes in Code Status During the COVID-19 Pandemic and the Implications for Future Pandemic Care.

Objective: We aim to explore patterns of inpatient code status during the COVID-19 pandemic compared with a similar timeframe the previous year, as well as utilization of palliative care services.Methods: This is a retrospective cohort study using data from the Montefiore Health system of all inpatient admissions between March 15-May 31, 2019 and March 15-May 31, 2020. Univariate logistic regression was performed with full code status as the outcome. All statistically significant variables were included in the multivariable logistic regression.Results: The total number of admissions declined during the pandemic (16844 vs 11637). A lower proportion of patients had full code status during the pandemic (85.1% vs 94%, P < .001) at the time of discharge/death. There was a 20% relative increase in the number of palliative care consultations during the pandemic (12.2% vs 10.5%, P < .001). Intubated patients were less often full code (66.5% vs 82.2%, P < .001) during the pandemic. Although a lower portion of COVID-19 positive patients had a full code status compared with non-COVID patients (77.6% vs 92.4%, P<.001), there was no statistically significant difference in code status at death (38.3% vs 38.3%, P = .96).Conclusions: The proportion of full code patients was significantly lower during the pandemic. Age and COVID status were the key determinants of code status during the pandemic. There was a higher demand for palliative care services during the pandemic.

The relationship between self-efficacy and treatment satisfaction among patients with anticoagulant therapy: a cross-sectional study from a developing country

BackgroundThromboembolic events are a common complicated health problem. Although anticoagulants have several positive effects on these conditions, they also have several characteristics that strongly affect compliance and satisfaction. The purpose of this investigation is to explore the association between treatment satisfaction and self-efficacy in a sample of patients using anticoagulation therapy and determine the influence of sociodemographic and clinical factors on both aspects.MethodsThis was a cross-sectional exploratory study carried out in Palestine. The Arabic version of the Anti-Coagulant Treatment Satisfaction Scale (ACTS) assessed treatment satisfaction. In addition, the Arabic version of the 6-Item Self-Efficacy for Managing Chronic Diseases (SES6C) was used to assess self-efficacy.ResultsA total of 300 patients using anticoagulants (average age 51.95 and SD 17.98) were included. There is a modest correlation between treatment satisfaction and self-efficacy (r = 0.345; p < 0.001). The mean and median self-efficacy scores were 38.41 ± 9.88 and 39.00 (interquartile range: 33.00–46.00), respectively. Overall, patients reported a moderate burden and benefit score. The mean and median of the acting burden were 43.30 ± 10.45, and 43.30 (interquartile range: 36.00 to 51.00), respectively. The results showed that young age, higher education, employment, use of fewer medications, and having fewer diseases were significantly associated with higher self-efficacy behaviors. The results also showed that new oral anti-coagulants (NOACs) had a higher degree of self-efficacy and ACTS benefit scores (41.00 (33.75–47.00), p = 0.002; 13.00 (12.00–15.00), p < 0.001, respectively), than vitamin k antagonists (VKA).ConclusionsThe results demonstrated a significant relationship between treatment satisfaction and self-efficacy, and certain sociodemographic and clinical characteristics influence both. We found that there is a higher degree of self-efficacy and treatment satisfaction among patients who use NOACs than those who use UFH / VKA. Therefore, patients should be motivated to increase their knowledge about anticoagulant therapy. Healthcare providers should play an active role in educating patients, increasing their self-esteem, and awareness about anticoagulant drugs. Importantly, this study was an explanatory one, and it includes a low proportion of patients with venous thromboembolism. This encourages future research on a large scale of patients, considering the indications of anticoagulant therapy.